 Vir Biotechnology Inc NASDAQ: VIR announced new preclinical data, published to the preprint server bioRxiv , demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant B.1.1.529. A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. 